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Abstract 
Theoretical considerations as well as clinical 
observations suggest that the aggregation of nucleated 
crystals is the most dangerous step in the formation of 
calcium oxalate (CaOx) renal stones. The effects of 2 
major urinary glycoproteins , Tamm-Horsfall glycopro-
tein (THP) and Nephrocalcin (NC), on calcium oxalate 
monohydrate (COM) crystal aggregation in vitro are 
studied. At low ionic strength (IS) and high pH (within 
urinary limits) , THP is a powerful crystal aggregation 
inhibitor (90% inhibition at 40 mg/I) . Decreasing pH to 
5.7 and raising IS to 0.21 incr eases THP viscosity, 
thereby lowering THP crystal aggregation inhibition . 
Upon addition of calc ium (5 mmol /1), some THPs are no 
more soluble and promote crystal aggregation (up to 
70 %) . In the presence of citrate (5 mmol/1) , which is 
only slightly inhibitory (14 %) , the promoting effect of 
THP is reversed into aggregation inhibition (up to 55 % ) . 
There is evidence for a molecular abnormality in THPs 
from severe recurrent CaOx stone formers, since they 
exhibit increased polymerization and reduced solubility. 
The 14 kD (kilodalton) , Gia-containing glycoprotein NC 
also strongly inhib its crystal aggregation . However, NC 
isolated from urines of recurrent CaOx stone formers 
and from CaOx renal stones are 10 times less inhibitory. 
Both are structurally abnormal in that they lack Gia and 
are less amphophilic . 
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Renal stone formation occurs as a consequence of 
crystallization within the urinary tract. Crystallization 
has two major aspects (19): a thermodynamic one in-
cluding high urinary supersaturation during which crys-
tal nucleation occurs, and a kinetic one comprising rates 
of nucleation , growth and aggregation (agglomeration) 
of crystals. 
Calcium oxalate crystalluria is a common feature 
in recurrent renal stone formers as well as in healthy 
people (10, 33). Under identical conditions of dietary 
and fluid intake, however , healthy controls excrete only 
single calcium oxalate crystals 3-4 µm in diameter, 
whereas recurrent calcium stone formers pass large cal -
cium oxalate crystals (10- 12 µm diameter), often fused 
into polycrystalline aggregates 20-300 µm in diameter 
(31). Furthermore, inhibition of the formation of large 
calcium oxalate crystal aggregates in vitro by 5 vol% hu-
man urine is reduced in recurrent calcium stone formers 
(32), and renal stones contain highly aggregated crystals 
(23). These observations clearly suggest that calcium 
oxalate crystal aggregation may be more important for 
renal stone formation than crystal nucleation and 
growth. This is supported by theoretical considerations: 
calcium oxalate crystal growth alone might be too slow 
to produce clinically significant particles within renal tu-
bules (9), whereas crystal aggregation occurs within sec-
onds and is, therefore, considered to be much more dan-
gerous for the formation of large crystalline particles 
within the urinary tract (4). 
There are two main reasons why the urinary com-
pounds that modify calcium oxalate crystal aggregation 
are not well defined. First, there is some confusion in 
the literature about the definitions of "crystallization" 
and "inhibitory activity" (33). In many studies on "crys-
tallization", it is not completely clear whether authors 
refer to nucleation, growth or aggregation of crystals. 
On the other hand, the term "inhibitor" is being used for 
compounds that act as chelators of calcium or oxalate as 
well as for molecules binding to the surface of pre-
formed calcium oxalate crystals (33) . Whereas chelators 
clearly reduce free ion activity and supersaturation, in-
hibitors do not influence supersaturation, since they bind 
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Figure 1. Spontaneous sedimentation of COM crystals. 
COM crystal suspensions (0 .8 mg/ml) were incubated 
overnight at 37 °C under constant stirring (1 JOO rpm) in 
16 x 125 mm glass tubes and then kept standing at room 
temperature. At time zero (upper panel) , there was no 
visible difference between control crystals (right) and 
crystals pre -incubated with 16 mg/1 of normal human 
THP. After 60 minutes (lower panel), particles in the 
control suspension had settled almost completely, where -
as settling was clearly retarded in the presence of THP 
(left). 
Table 1. Basic forces determining crystal aggregation 
in stirred suspensions• . 
Aggregating Disaggregating 
► Van der Waals 
► Viscous binding 
► Electrostatic repulsion Foreign molecules = 
---..Js 
"glue" 11 Zeta potential 
~J ► Shear force Turbulence of aqueous 
► Solid bridges suspensions (stirring) 
--1 , --v Stabilization 
• Adapted from reference 20 . 
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to crystal surfaces and block growing sites ("crystal poi-
soning") at very low (usually micromolar) concentrations 
(2) . On the other hand, some molecules act as promo-
ters , probably by providing preformed surfaces for het-
erogeneous nucleation , epitaxial growth and aggregation 
of crystals (2). Because compounds can have varying 
effects on different crystallization processes , the term 
"modifier" should be used (43), and it should always be 
stated whether a speci fie molecule inhibits/promotes 
nucleation , growth or aggregation of crystals (33) . 
The second reason , why urinary modifiers of cal-
cium oxalate crystal aggregation are poorly understood , 
is the variety of assay systems/conditions applied for 
measuring crystallization processes. In the case of crys-
tal aggregation, measurements usually have been made 
under conditions of supersaturation with respect to calci-
um oxalate, so simultaneous nucleation and growth 
might have alter ed crystal aggregation kinetics ( 4 , 7 , 32 , 
36, 39 , 44). 
During our own experiments focused on growth of 
calcium oxalate monohydrate (COM) crystals in a seeded 
system (unpublished) , we observed that spontaneous sed-
imentation of crystals suspended at equilibrium solution 
concentrations was retarded after preincubation with uri-
nary proteins (Fig . 1 ) . Since average sedimentation ve-
locity of particles falling through a liquid is directly pro -
portional to average particle size (17), more slowly set-
tling particles must be smaller. In a saturated solution , 
crystals can not nucleate nor grow . Since crystal aggre-
gation also occurs at saturation or even undersaturation 
(20) , smaller particles in an equilibrated crystal sus-
pension must be less aggregated . 
Table 1 summarizes the basic for ces by which 
crystal aggregates in solutions are held together (8): the 
attr ac tive van der Waals forces favor particle aggrega-
tion, whereas the electrostatic surface potential is repul -
sive (8 , 20) . The process of viscous binding implies that 
crystal foreign molecules are attached to crystal surfaces 
and act as a glue between particles , thereby promoting 
crystal aggregation (20). If crystalline material connects 
several particles (solid bridge formation) , the aggregate 
becomes more stable (20) . In a crystal suspension , con-
stant stirring (shear force) basically favors disaggrega-
tion (20) ; as expected , slower stirring produces more ag-
gregated particles ( 4) . Based on these observations, we 
have measured COM crystal aggregation in vitro by 
spectrophotometrically monitoring the sedimentation of 
crystals that have been pre-aggregated by slow stirring 
in an equilibrated suspension (13). It has to be acknowl-
edged, however, that under saturated conditions, macro-
molecular modifiers possibly might affect COM crystal 
aggregation differently from supersaturated conditions 
(20). This paper reviews recent work on two major 
urinary glycoproteins, Tamm-Horsfall glycoprotein and 
Nephrocalcin, with regard to their effects on calcium 
oxalate crystallization processes in vitro. 
Calcium oxalate - Tamm-Horsfall glycoprotein & Nephrocalcin 
Table 2. THP inhibition of calcium oxalate crystallization processes in vitro•. 
Nucleation Growth Aggregation 
% inhi- +19 ~ -250 +38 ~ 0 +90 ~ -35 
bition 
[THP] 50 35 50 8 40 40 
mg/I 
pH 6.5 5.3 6.5 5.7 7.2 5.7 
IS 0.15 0.15 0.15 0.10 0.21 
Osmol. 1250 
mOem/kg 
Ref . 18 36 18 50 13 74 
*The most contradicting findings, taken from the literature, are listed . Lower part depicts physico-chemical conditions 
at which experiments were performed. Negative inhibition values = promotion. IS = ionic strength; Osmol. = 
Osmolality; Ref. = reference . 
Tamm-Horsfall Glycoprotein 
The pathophysiology of Tamm-Horsfall glycopro-
tein (THP), also called uromucoid, has been reviewed 
extensively (16, 21, 34). Briefly, THP is produced pri-
marily by the kidneys, where it is specifically localized 
to the epithelial cells of the thick ascending limb of 
Henle's loop and the most proximal part of the distal tu-
bule (21) . Biochemically, THP is a glycoprotein ; its 
carbohydrate content amounts to 30 % . In its monomeric 
form, THP isolated from urine by the original salt pre-
cipitation method has a molecular weight (MW) of 80 
kD (21). The THP gene recently has been cloned and 
sequenced; the mature protein contains 616 amino acids. 
A very similar protein, uromodulin, has been isolated 
from pregnancy urines by lectin adherence; its protein 
backbone is identical to THP. During pregnancy, the 
protein's carbohydrate structure may be altered; in fact, 
uromodulin contains more unprocessed high mannose 
chains and is at least 10 times more immunosuppressive 
in vitro than salt-precipitated THP (21). The exact func-
tion of THP remains enigmatic (16, 21, 34); recent 
studies suggest that THP might be a specific ligand for 
cytokines in the kidney (21). 
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Because THP is present in various amounts in re-
nal stones ( 12), it has been proposed to play a role in re-
nal stone formation . Several studies did not find a dif-
ference between normals and calcium oxalate stone for-
mers in the daily urinary excretion of THP, averaging 
40-50 mg (3, 12, 38, 47), with the exception of patients 
with distal renal tubular acidosis in whom THP excretion 
seems to be significantly lower (46). The many in vitro 
studies investigating the effects of THP on calcium 
oxalate crystal nucleation, growth and aggregation seem 
to have revealed very contradicting results. Table 2 
depicts the most conflicting values currently available 
from published studies. Kitamura and Pak reported 19 % 
inhibition of calcium oxalate crystal nucleation by 
normal human THP at 50 mg/1, pH 6.5, 1 mM CaC12 
and ionic strength (IS) 0 . 15 (18). At otherwise identical 
conditions, but pH 6.0, Yoshioka et al. found promotion 
of nucleation by 25% (50). The addition of THP (only 
1 mg/1) to synthetic urine in a mixed suspension, mixed 
product removal analytic system with very high calcium 
(6. 76 mM) and oxalate (l.03 mM) concentrations at pH 
5.7 promoted nucleation by 183% (6) . Finally, upon ad-
dition of 35 mg THP to 1 liter of extremely concentrated 
urine (evaporated to 1250 mOsmole/kg) at pH 5.3, nu-
cleation of amorphous calcium oxalate crystals increased 
by 250 % (35) ! 
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~ RCSF D Normals 
Figure 2. COM crystal aggregation inhibition by nor-
mal and stone former THP. COM crystal aggregation 
inhibition (%) is measured at pH 5. 7, 200 mM NaCl and 
5 mM CaCl 2 . A = crystal aggregation; Ac = aggrega -
tion in control experiments (no inhibitor added, 0% inhi-
bition); ATHPP = aggregation in the presence of 40 mg/1 
of THP from 6 normal men (normals) and 5 recurrent 
calcium oxalate renal stone formers (RCSF) . Values are 
mean ± SEM . Negative inhibition values = promotion 
of crystal aggregation . 
Most authors agree that THP is a weak inhibitor 
of calcium oxalate crystal growth in vitro . At pH 6.0 , 
IS 0.15 , 1 mM CaC12 chloride and 0.2 mM sodium oxa -
late, 50 mg/1 of normal THP inhibited by 3 % (50); at the 
same IS, but pH 6.5 and only 0.44 mM calcium and oxa-
late, respectively , 50 mg/I THP from stone formers inhi-
bited by 38% (18) . In a study performed at pH 5.7, JS 
0.15, 1 mM calcium and 0.2 mM oxalate, crystal growth 
was not affected by 8 mg/I of THP (49). 
Measuring calcium oxalate crystal aggregation 
(agglomeration) in vitro in the presence of 5 vol. % hu-
man urine before/after removal of THP by antibody pre-
cipitation, Felix et al . (7) could not detect an inhibitory 
effect of THP . Scurr and Robertson, however, found 
22 % aggregation inhibition by 48 mg/I of isolated THP 
at pH 6.0, JS 0.15, 2 mM calcium and 0.4 mM oxalate 
(39). Upon addition of oxalate to metastably supersatu-
rated ultra-filtered human urine in the presence of isolat-
ed THP (50 mg/I), predominantly small crystals of calci-
um oxalate monohydrate instead of aggregated calcium 
oxalate dihydrate "envelopes" are formed (37) . Using 
the newly developed spectrophotometric method at pH 
7.2, IS 0.1 and only equilibrium concentrations of calci-
um and oxalate, e.g ., 0.14 mM each, we found about 
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90% aggregation inhibition by normal human THP at 40 
mg/I (13) . In a subsequent study, however, lowering pH 
to 5. 7 and increasing IS to 0.21 at otherwise unchanged 
conditions revealed 35 % promotion of aggregation by 40 
mg/1 of THP isolated directly from calcium renal stones 
(14). 
These apparently paradoxical influences on the 
various crystallization processes may be explained by the 
well-known physicochemical properties of THP: in-
creasing the concentrations of the protein itse l f (22), di-
valent cations like calcium and magnesium (5 , 4, 6) , so-
dium (22, 45) and hydrogen ions (22) all induce in-
creased polymerization (self aggregation) of THP mole-
cules, leading to reversible gel formation (increased vis-
cosity) (11). Scanning electron microscopy studies re-
vealed that THP molecules formed elongated fibers 
about 20 nm thick and up to 1000 nm long in solutions 
containing NaCl (100 mmol/1) or CaCI2 (1 mmol/1); 
when NaCl plus CaCl 2 were present , however, thick 
bundles of fibers, as found in hyaline casts from human 
urine, could be seen ( 48). It is obvious from table 2 that 
less THP inhibition or even promotion of calcium oxa-
late crystallization processes occurred in those studies 
performed at lower pH and higher IS . 
Studying the effects of increasing IS from 0 .01 to 
0.21 at pH 5 .7 on individually purified THPs (40 mg/I) 
from normal men and male patients with severe recur-
rent idiopathic calcium oxalate stone disease ( > 20 
stones), we found reduced COM crystal aggregation in-
hibition in all proteins, but more markedly in stone 
former THPs (15) . This was not simply due to lower 
solubilities of patient THPs at the experimental condi-
tions (15), but seems to be the consequence of a molecu-
lar THP abnormality in patients with severe calcium 
oxalate nephrolithiasis: stone former THP exhibits an 
increased tendency to polymerize at lower pH and higher 
IS , as evidenced from viscosity measurements and mole-
cular weight determinations (15). Studies on THPs of 
the family members of one severe stone former indicate 
that this abnormality might be inherited. The molecular 
basis of this apparent structural abnormality, however, 
remains unknown (15). 
Most recently, we studied the effects of high 
physiological calcium and citrate concentrations on 
COM crystal aggregation inhibition by individual THPs. 
After equilibrating COM crystals in 200 mM NaCl and 
5 mM CaC12 at pH 5. 70, the rate of crystal aggregation 
was identical to the one originally described without ad-
ditional calcium (13). Urinary THPs of 6 healthy men 
and 5 severe male idiopathic calcium stone formers (10-
200 stones) were studied by adding low amounts of high-
ly concentrated aqueous THP solutions to a final assay 
concentration of 40 mg/I. Normal THPs (values mean 
± standard error of mean, SEM) inhibited by 13.7 ± 
8.8% (range -3.0% to 50.1 %), stone former THPs by -
31.4 ± 12.6% (range -68.0 to 7.4%, p < 0.01 versus 
normal THPs), e.g . , most stone former proteins actually 
promoted crystal aggregation (Fig. 2). Citrate at 5 
mmol/1, without any effect on crystal aggregation if no 
Calcium oxalate - Tamm-Horsfall glycoprotein & Nephrocalcin 
additional calcium was present (13), inhibited by 14.3 ± 
3.82% (n=lO). When we restudied the 2 most promot-
ing stone former THPs in the presence of 5 mM citrate, 
however, promotion was reversed into inhibition, e.g., 
inhibition changed from -68 % and -45 % (Fig. 2, far left) 
to + 55 % and + 34 % , respectively (not shown), clearly 
above the slight inhibition by citrate alone. Similar re-
sults were obtained with studies in whole urine of our 
most severe stone former (200 stones). Crystal aggrega-
tion inhibition was measured after incubating unfiltered 
fresh 24 hour urine with COM crystals for 36 hours; in-
hibition was -54 % , e.g., whole urine promoted crystal 
aggregation. Since urinary calcium was relatively much 
higher than citrate (4.64 versus 1.88 mmol/1), citrate 
was added to a final concentration of 6.88 mmol/1; re-
measuring crystal aggregation revealed true inhibition of 
88%. 
Most authors agree that the mechanism, by which 
urinary macromolecules inhibit crystal aggregation in 
vitro, is their binding to the crystals, which induces a 
more negative surface charge (Zeta potential) on the 
crystal surface (8, 39). In comparison with glycosami-
noglycans and RNA, however, THP produces a less ne-
gative Zeta potential on COM crystals (39). Further-
more, two studies have demonstrated that upon raising 
THP concentrations within physiologic urinary limits, 
e.g., above 10-7 M, Zeta potential does not become any 
more negative, e.g., the potential curve flattens off at 
about -20 mV (13, 39). Our own studies did not reveal 
Zeta potential differences between THPs from healthy 
men and severely recurrent stone formers, nor was COM 
crystal aggregation inhibition by physiologic THP con-
centrations correlated to Zeta potential values (15). 
We found, however, a negative linear correlation 
between crystal aggregation inhibition and intrinsic 
viscosity of THP at pH 5. 7 and 200 mM NaCl, e.g., 
THPs with lower viscosities allowed for more crystal ag-
gregation inhibition (14, 15). In accordance with others 
(22, 40), our most recent data obtained at pH 5. 7, 200 
mM NaCl and 5 mM CaCl 2 suggest an additional role of 
THP solubility: measured at room temperature as des-
cribed elsewhere (15), THP solubility (mean ± SEM) 
was 61.0 mg/I for normal and 34.8 mg/I for stone for-
mer THP (p < 0.01). When adding 40 mg of dry stone 
former THP to 1 liter buffer solution (pH 5. 7, NaCl 200 
mM, CaCl 2 5 mM), visible hair-like precipitates were 
regularly detectable . 
Altogether, there is strong evidence for a dual 
role of THP in COM crystal aggregation. At higher pH 
and lower IS, THP is a powerful aggregation inhibitor. 
Upon lowering pH and raising IS within physiologic uri-
nary limits, increased polymerization of THP molecules 
occurs. This most possibly increases attractive viscous 
binding forces on COM crystal surfaces. Since the re-
pulsive Zeta potential is not increased any further, the 
overall forces between crystals become more attractive, 
allowing for more crystal aggregation (reduced inhibi-
tion). If in addition high physiological calcium concen-
trations are present, certain THPs even may form 
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insoluble precipitates on which crystals preferably 
aggregate (promotion of aggregation). This seems to be 
reversed by equimolar concentrations of citrate, suggest-
ing a higher affinity of calcium ions to citrate than to 
THP. As our recent data indicate, some stone former 
THPs have an increased tendency of polymerization and 
lower solubilities than normal THPs. These findings, 
however, do not exclude that, in a given clinical 
situation, an extreme difference in the chemical compo-
sition of urine between stone formers and normals might 
in itself produce various THP effects irrespective of 
molecular THP abnormalities. 
Nephrocalcin 
In 1978, Nakagawa et al. (24) isolated an acidic 
glycoprotein from human urine which strongly inhibited 
the growth of COM crystals in vitro. Subsequently, the 
same glycoprotein was also purified from human kidney 
tissue culture medium (25). Since further characteriza-
tion demonstrated that the protein contained gamma-
carboxyglutamic acid (Gia) (26), it later was named 
nephrocalcin (NC), in analogy with osteocalcin, the Gia-
containing bone protein (28). In its monomeric form, 
NC has a molecular weight of 14 kD; it contains calcium 
and magnesium ions that are likely to be involved in the 
formation of aggregates of higher molecular weights in 
human urine (26). NC is rich in acidic amino acids and 
contains 10 weight% of carbohydrates (26); it does not 
contain any uronic acids (30). The glycoprotein shows 
a strong surface activity as evidenced by a very high 
collapse pressure at air-water interfaces, suggesting 
strong amphophilic properties and a highly organized 
two-dimensional structure of NC (26). 
There are several lines of evidence for a renal ori-
gin of NC. To date, NC has been isolated from kidney 
tissue of nine vertebrae species (30). Primary cultures 
of mouse proximal tubule cells produce NC (42). Renal 
cell cancers, which are believed to originate from proxi-
mal tubule cells, seem to produce NC as well, as evi-
denced from the purification of NC from the culture 
medium of renal carcinoma cells (41). Immunohisto-
chemically, NC could be localized to the proximal tubule 
and the thick ascending limb of Henle' sloop in mouse as 
well as in human kidneys; there was no cross-reactivity 
with THP (29). Daily urinary excretion of NC in hu-
mans amounts to about 20 mg; there seems to be no dif-
ference between normals and renal stone formers (M. 
Netzer, personal communication). 
NC isolated from normal human urine is a strong 
inhibitor of COM crystallization processes in vitro. 
Using a constant composition assay, Asplin et al. recent-
ly demonstrated that NC (as well as 20 % dialyzed hu-
man urine) inhibited the secondary nucleation of calcium 
oxalate on COM crystals as well as crystal growth (1). 
By means of a seeded crystal growth system, NC puri-
fied from normal human urines and from human kidney 
tissue culture medium repeatedly has been shown to 
strongly inhibit COM crystal growth at concentrations 
between 10-9 and 10-6 M (25-28, 49). Our own studies 
B. Hess 
demonstrated that normal NC at concentrations between 
5 x 10-8 and 1 x 10-6 M also is a powerful inhibitor of 
COM crystal aggregation (13). Opposite to THP, in-
creasing ionic strength or lowering pH of the solution 
did not affect the inhibitory activity of normal NC at 
physiologic concentrations (13). 
Considering the mechanism of NC inhibition, it 
is important to note that patients with recurrent calcium 
oxalate nephrolithiasis produce a structurally defective 
NC (27); NC with the same abnormalities has also been 
isolated from human calcium oxalate renal stones (28). 
Both stone former and stone NC lack gamma-carboxy-
glutamic acid, are less amphophilic (formation of less 
stable air-water interfacial films) and induce a less nega-
tive Zeta potential on COM crystal surfaces (I 3, 27, 
28). Functionally, stone former as well as stone NC are 
weak crystal aggregation inhibitors at physiologic con-
centrations (about 10-fold less effective than normal 
NC); however, increasing their concentrations above the 
physiologic range raises inhibitory activity to normal 
levels (13). Since progressively increasing the concen-
trations of these defective NCs improves their inhibitory 
activity yet does not alter crystal surface charge (13), we 
conclude that their weaker amphophilic properties, 
possibly due to the lack of gammacarboxyglutamic acid, 
may be responsible for the loss of COM crystal aggrega-
tion inhibition . One might speculate that conformational 
changes in the defective forms of NC, when bound to 
COM crystals, allow for relatively more viscous binding 
on the crystal surface. However, promotion of crystal 
aggregation, as found in abnormal THP, has never been 
demonstrated for defective NC. 
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Discussion with Reviewers 
W.G. Robertson: Why under certain conditions does 
THP appear to exert an inhibitory effect on agglomera-
tion yet, according to the author, does not show any re-
lationship with Zeta potential? 
Author: The extent of crystal aggregation (agglomera-
tion) in vitro is determined by attractive and repulsive 
forces that are balanced against each other (Table 1). 
As demonstrated by your group (40) and our own results 
(13), increasing THP concentration within physiologic 
limits does not change Zeta potentials. Therefore, given 
constant stirring rates in our system, the overall repul-
sive force remains constant, and increased THP inhibi-
tion (less crystal aggregation) must be the consequence 
of reduced attractive forces. We find that THPs with 
low viscosities, e.g., less polymerized molecules, inhibit 
crystal aggregation more markedly than THPs with high 
viscosities (14, 15). One explanation would be that low 
viscosity THP molecules, compared to more viscous 
THP polymers, produce less viscous binding, which 
would lead to a relative increase of net particle repul-
sion, e.g., more crystal aggregation inhibition. 
W.G. Robertson: Is there any relationship between the 
structure of NC and that of part of the THP molecule as 
was suggested by one group? 
Author: I cannot answer this question, since the 
primary structure of NC is still under investigation. 
S.R. Khan: What happens to the calcium oxalate zeta 
potential in the presence of NC? 
Author : As demonstrated by our own studies ( 13), NC 
also induces a negative Zeta potential on COM crystals. 
Similar to THP, increasing NC concentrations within 
physiologic urinary limits does not raise any further the 
negative Zeta potential, e.g., the potential curve flattens 
off at about -18 mV. Defective NCs, isolated either 
from stone former urines or directly from CaOx renal 
stones, induce a less negative Zeta potential of about -13 
mV on COM crystal surfaces (13). 
M. Akbarieh and R. Tawashi: Increasing THP concen -
tration, increasing the IS and changing pH could lead to 
increased aggregation (polymerization!) of the protein. 
What critical precaution the author suggests in the prep-
aration and purification that could minimize the effect of 
these variables? 
Author: We routinely purify THP from human urines 
by the classical method of repeated salt precipitation, 
modified, however, by using 4 M urea in 0.02 M sodium 
phosphate, pH 6.8, and gel filtration (Sepharose 4B) as 
a final purification step (13). This minimizes the effect 
of pH and IS; in addition, increasing the urea concentra-
tion is known to decrease THP viscosity (16, 21). 
N. Akbarieh and R. Tawashi: The author speculates 
that the structurally defective forms of NC present in 
stone former urines and renal stones lead to viscous 
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binding of COM crystals . If this is true, does the 
production of Jess negative charge on COM crystal 
surface really matter? 
Author: As mentioned above, it is purely speculative to 
state that defective forms of NC might allow for more 
viscous binding on COM crystal surfaces. This was done 
in analogy to THP, where increasing concentrations 
within the physiologic range also do not raise the nega-
tive Zeta potential yet inhibitory activity changes (see 
also my answer to first question by Prof. Robertson). 
Therefore , I agree, that the negative Zeta potential does 
not seem to contribute really to the differences in COM 
crystal aggregation inhibition that we observe, at least 
not under our experimental conditions and at the (phys-
iologic) concentrations of both THP and NC we have 
chosen for our studies. 
D.J. Kok: Is there a correction applied for the differ-
ence in density between single crystals and their aggre-
gates? 
Author: I am aware of the fact that the density of crys-
tals and their aggregates does not have to be identical; 
however, no such correction was applied in our in vitro 
system. 
D.J. Kok: It has been shown before that the effect of 
citrate on crystal agglomeration depends on the type of 
complexes formed in solution. It can be increased by 
the presence of magnesium or by changing the calcium 
concentration. What evidence does the author have that 
this is not the case here? 
Author: Magnesium was never present in our assay sol-
utions. We can , however, demonstrate an increased in-
hibitory effect of citrate upon formation of calcium -
citrate complexes. Previously, when calcium was pres-
ent only at equilibrium concentration (0.14 mM) in our 
system (13), we had not found any effect of millimolar 
citrate concentrations on COM crystal aggregation. The 
experiments presented in this paper were performed with 
5 mM calcium and, therefore, allowed for calcium-cit-
rate complex formation; in fact, we demonstrate 14.3% 
inhibition by 5 mM citrate. Our most recent studies (un-
published) indicate a 45 % increase of aggregation inhibi-
tion by normal THPs after addition of citrate, consider-
ably more than with citrate alone . This additional in-
crease must be related to THP itself, possibly because 
calcium is mainly chelated by citrate and can no longer 
induce conformational changes of THP molecules (poly-
merization) to the same extent. 
D.J. Kok: The structural changes in THP and NC may 
represent two different groups of calcium oxalate stone 
formers or there may be some (cellular?) aberrance con-
necting both. Does the author have any information 
supporting one of these hypotheses? 
Author: I do not have any information on either of the 
two hypotheses. 
